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Spermine increases acetylation of 
tubulins and facilitates autophagic 
degradation of prion aggregates
Kanchan Phadwal1, Dominic Kurian1, Muhammad Khalid F. Salamat1, Vicky E. MacRae1, 
Abigail B. Diack  1 & Jean C. Manson1,2,3
Autolysosomal dysfunction and unstable microtubules are hallmarks of chronic neurodegenerative 
diseases associated with misfolded proteins. Investigation of impaired protein quality control and 
clearance systems could therefore provide an important avenue for intervention. To investigate this we 
have used a highly controlled model for protein aggregation, an in vitro prion system. Here we report 
that prion aggregates traffic via autolysosomes in the cytoplasm. Treatment with the natural polyamine 
spermine clears aggregates by enhancing autolysosomal flux. We demonstrated this by blocking the 
formation of mature autophagosomes resulting in accumulation of prion aggregates in the cytoplasm. 
Further we investigated the mechanism of spermine’s mode of action and we demonstrate that 
spermine increases the acetylation of microtubules, which is known to facilitate retrograde transport 
of autophagosomes from the cellular periphery to lysosomes located near the nucleus. We further 
report that spermine facilitates selective autophagic degradation of prion aggregates by binding to 
microtubule protein Tubb6. This is the first report in which spermine and the pathways regulated by it 
are applied as a novel approach towards clearance of misfolded prion protein and we suggest that this 
may have important implication for the broader family of protein misfolding diseases.
Accumulation and aggregation of misfolded proteins are hallmarks of neurodegenerative disorders, such as 
Alzheimer’s (AD), Parkinson’s, Huntington’s and prion diseases. These diseases many of which are strongly 
linked with age are debilitating and largely untreatable conditions. Considerable research has been directed 
towards understanding common pathological mechanisms that might be amenable to therapeutic intervention. 
Enhancing the pathways responsible for aggregate clearance such as autophagy is emerging as an important ther-
apeutic approach in these disorders.
Autophagy is a highly conserved cellular degradation mechanism where the double membrane autophago-
somes engulf the unwanted organelles, aggregates or cytoplasmic contents and pass them over to single mem-
brane lysosomes for degradation. Fusion of autophagosomes with lysosomes forms a hybrid vesicle compartment 
called an autolysosome, these autolysosomes can be visualised by blocking the degradation via lysosomes. For 
healthy functional autophagic machinery all the elements of the pathway play a crucial role i.e. autophagosome 
formation, maturation of autophagosomes, engulfment of the cargo, trafficking of the autophagosomes, fusion 
of autophagosomes with lysosomes, lysosome numbers and rate of fusion of these vesicles. Compromise in any 
one on its own or together with other elements of the pathway leads to the failure of the autophagic machinery 
which can lead to plethora of pathophysiological defects1. It has been demonstrated that suppression of autophagy 
in neural cells leads to accumulation of ubiquitinated protein aggregates and subsequent neurodegeneration in 
mice2,3. Additionally upregulation of the bulk protein degradation process of autophagy has been shown to clear 
disease-associated proteins, such as mutant alpha-synuclein, ataxin-3, tau, huntingtin, TDP-43 and disease asso-
ciated prion protein (PrPSc) in various in vivo and in vitro models4–9.
Prion diseases provide a highly controlled and well-defined model system to study the course of the neu-
rodegenerative disease process both in vivo and in vitro. Prion diseases are caused by the conversion of a nor-
mal cell-surface glycoprotein PrPC to a misfolded protease resistant form, PrPSc, which accumulates in the CNS 
leading to neurotoxicity and clinical disease. Disease associated prion protein can inhibit the 26S proteasome 
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leading to impairment of the ubiquitin-proteasome system (UPS)10. In the absence of a functional UPS, the 
autophagosomal-lysosomal pathway is known to target insoluble protein aggregates for degradation11. Inducing 
autophagy using trehalose12, lithium13, rapamycin8 resveratrol14 and celecoxib derivatives AR-1215 has shown 
protection against prion infectivity in in vitro model systems. Furthermore, treatment with rapamycin and resver-
atrol has shown delayed disease onset in in vivo prion models8,14, although the precise mechanisms remain to be 
determined.
Likewise, polyamines spermine and spermidine are known inducers of autophagy and their synthesis and 
metabolism is inherent to the eukaryotic system. In the polyamine biosynthetic pathway, spermidine is a precur-
sor of spermine and is a known promoter of longevity16,17. Spermidine has also been shown to prevent sporadic 
prion formation in yeast prion models18. Both enhancing longevity and protection against de novo formation of 
yeast prions by spermidine are shown to be autophagy dependent. Out of the several polycation tested for effec-
tively eliminating PrPSc, dextran-spermine a cationic polysaccharide version of spermine was determined to be 
most potent antiprion agent19. Spermine has also been shown to be the most effective inhibitor of nucleic acid 
induced polymerisation of human recombinant prion protein20 and is a known inducer of autophagy21. Given the 
enhanced efficacy of spermine over spermidine we investigated if and how spermine can clear prion aggregates.
We used prion infected cell cultures as a highly controlled model of chronic neurodegeneration to show that 
spermine at a physiological dosage22 can not only clear the prion aggregates but can also reduce cellular neuro-
toxicity by reducing the levels of cytosolic reactive oxygen species, ROS. This clearance of prion aggregates is 
autophagy dependent. Furthermore, treatment with spermine enhances the expression of microtubule proteins 
required for efficient retrograde transport of autophagic vesicles from the cellular periphery to the lysosomes in 
the cytoplasm. Finally, we report how spermine treatment targets prion aggregates to autophagosomes by binding 
with a microtubule protein Tubb6. Our results suggest multiple effects of spermine in the prion protein aggrega-
tion model. Its effect on enhancing autophagy, aggresome formation and acetylation of microtubules make it a 
potential therapeutic target for a broad family of protein misfolding diseases.
Results
Prion aggregates traffic via autolysosomes in SMB.s15 cells. We used the scrapie mouse brain 
(SMB) cell line infected with prion aggregates PrPSc (SMB.s15) and without prion aggregates (SMB-PS)23 for our 
study. We confirmed the presence of proteinase K (PK) resistant disease associated PrPSc both by immunostaining 
and immunoblotting with anti-prion antibody BC6. PrPSc bands were observed only in SMB.s15 cells but not in 
SMB-PS cells (Fig. 1a,b). We assessed both cell lines for basal levels of autophagy by measuring the conversion of 
autophagosome marker LC3-I to LC3-II by western blot (WB) after treatment with and without 10 μM of chlo-
roquine (CQ) for 16 hrs. Increased conversion of LC3-I to LC3-II by blocking the autophagic flux with CQ is an 
indicator of enhanced autophagosome formation. Furthermore, incubating the cells with 10 μM CQ for 16 hrs 
results in the build-up of acidic vesicles such as lysosomes, autophagosomes and autolysosomes24. We observed 
an increased expression of LC3-II in SMB.s15 cells when compared to SMB-PS by WB. However, a complete con-
version of LC3-I to LC3-II was not observed after CQ treatment (Fig. 1c), possibly indicating insufficient mature 
autophagosomes. Further analysis of the SMB cell lines by transmission electron microscopy (TEM) showed a 
clear accumulation of aggregate like bodies inside vesicles in the SMB.s15 cells but not in the SMB-PS after CQ 
treatment (Fig. 1d,e). These vesicles were observed with single membranes indicating that they may be autolys-
osomes. SMB.s15 cells also showed the presence of increased PrPSc on CQ treatment on WB (Fig. 1f). All these 
experiments established SMB.s15 as a convincing model of protein aggregation enabling us to investigate the role 
of autophagy in clearance of these aggregates.
We further confirmed whether the vesicles observed under TEM are autolysosomes and whether the aggre-
gates inside these vesicles are PrPSc aggregates. Cells were treated with CQ to block the degradation via lysosomes. 
5 M guanidine isothiocyanate treatment after fixation was used to expose the PrPSc epitopes25. Cells were stained 
with either proteostat dye (PS), which binds to protein aggregates, and the autophagy marker LC3 (Fig. 1g,h) 
or anti-prion antibody BC6 and LC3 (Fig. 1i,j). Staining of aggregates both with the PS dye and BC6 antibody 
showed the presence of punctate LC3 staining surrounding aggregates on CQ treatment, thus suggesting the pres-
ence of mature autophagosomes or autolysosomes around PrPSc aggregates. Together these results clearly indicate 
that prion aggregates traffic via mature autophagosomes or autolysosomes.
Spermine treatment clears prion aggregates in SMB cells and CAD cells terminally differenti-
ated into neurons and reduce ROS production in CAD cells. Given that spermidine protects against 
de novo formation of yeast prions18 and role of dextran-spermine in PrPSc clearance in chronically infected 
N2a-M cells19, we investigated if spermine has a similar effect in SMB and CAD22L cells (CNS catecholamin-
ergic cells infected with the prion agent 22L)26. We performed an initial investigation using both spermidine 
and spermine towards clearance of PrPSc aggregates. The dosage which was found to be equally effective both 
in spermidine and spermine were compared using immunoblotting after 72 hrs of treatment (Supplementary 
Fig. 1a). Spermine was consistently found more effective compared to spermidine; hence we decided to further 
investigate spermine only. We primarily determined the correct dosage of spermine; at 20–100 μM extensive cell 
death was observed and at the lower concentrations (1–4 μM) the cells remained viable but no clearance of PrPSc 
was observed. However, treatment with an intermediate dose of 5 μM of spermine was found to be consistently 
effective in clearing prion aggregates and the cells survived as untreated cells. Dose dependent cell viability was 
assessed using MTT assay (Supplementary Fig. 2a1). We then stained the cells with BC6 and observed a sig-
nificant reduction in the intensity of PrPSc in a time dependent manner (Fig. 2a,b). A significant reduction in 
total PrPSc was also observed on WBs of cell extracts (Fig. 2c,d). In particular, a significant reduction in both 
the di- and mono- glycosylated forms were observed after 72 hrs of treatment (Fig. 2c,e), confirming that 5 μM 
spermine is able to effectively reduce the levels of PrPSc in SMB.s15 cells. We further applied spermine treatment 
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in CAD22L cells that were terminally differentiated into neurons and observed similar results as seen in SMB.
s15 cells after 72 hrs of treatment with 5 μM spermine, both by microscopy (Fig. 2f) and WBs (Fig. 2g–i) with the 
BC6 antibody. Oxidative stress is a known inducer of neuronal cell death associated with prion diseases27 and 
spermine is a known scavenger of ROS22. We used TMRE (tetramethylrhodamine, ethyl ester) which assesses 
changes in mitochondrial membrane potential (Δψm) and 2′,7′-dichlorofluorescin diacetate (DCFDA) assay 
to assess the levels of 2′,7′-dichlorofluorescein (DCF) fluorescence. Both of these assays are indicators of ROS. It 
has been previously demonstrated that mitochondria with increased membrane potential produce more ROS28. 
Figure 1. Prion aggregates traffic via autolysosomes in SMB.s15 cells. All the experiments were performed 
either with or without 10 μM CQ. (a) Immunofluorescence staining using anti PrP antibody BC6 in SMB-PS 
and SMB.s15 cells (N = 3). (b) Representative immunoblot shows PK resistant PrPSc in SMB.s15 cells (N = 2). 
(c) Representative immunoblot for LC3 and β-tubulin in SMB-PS and SMB.s15 cells, lane 2 & 4 were treated 
with CQ (N = 3). (d) Representative TEM images of SMB-PS and SMB.s15 after CQ treatment, red arrows 
indicate vesicles with aggregates (N = 2). (e) Increased number of vesicles with aggregates in SMB.s15 cells. 
All SMB.PS cells imaged with TEM showed minimal aggregates (0–5/cell) whereas all SMB.s15 cells images 
showed increased number of aggregates (5–24/cell). (f) WB for PK resistant PrPSc after CQ treatment in SMB.
s15 cells (N = 3). (g) Representative image of proteostat dye (aggregates) and LC3 immunofluorescence staining 
of SMB.s15 cells after CQ treatment compared to untreated control cells (N = 3). (h) Significantly increased 
LC3 stained proteostat positive aggregates in SMB.s15 cells on CQ treatment. (i) Representative image of PrPSc 
and LC3 immunofluorescence staining of SMB.s15 cells after CQ treatment compared to untreated control 
cells (N = 5). (j) Significantly increased LC3 stained PrPSc aggregates in SMB.s15 cells on CQ treatment. Scale 
bar = 10 μm. Respective full length blots are shown in Supplementary Fig. 3. Abbreviations used Chloroquine 
(CQ), Transmission Electron Microscopy (TEM), proteinase K (PK).
www.nature.com/scientificreports/
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We observed a significant decline in mitochondrial membrane potential (Supplementary Fig. 2a2) along with a 
significant decline in ROS levels after 72 hrs of spermine treatment (Fig. 2j,k) in CAD 22L cells. Thus, spermine 
treatment is not only able to clear PrPSc aggregates but also reduces the levels of ROS in prion infected cells.
Figure 2. Spermine treatment clears prion aggregates in SMB and CAD cells terminally differentiated into 
neurons and reduces ROS in CAD cells. SMB.s15 and CAD22L cells were treated with 5 μM spermine for the 
mentioned period. (a) Representative immunofluorescence images showing reduced PrPSc staining after 24 
and 72 hrs of spermine treatment in SMB.s15 cells (N = 3). (b) Significantly reduced pixel intensity of PrPSc in 
immunofluorescence images on 72 hrs spermine treatment in SMB.s15 cells. (c) Proteinase-K treated lysates 
immunoblotted for PrPSc after 0, 24 and 72 hrs of treatment with spermine in SMB.s15 cells (N = 3). (d) 
Significantly reduced relative density of total PrPSc after 72 hrs of spermine treatment. (e) Significantly reduced 
relative density of di- and mono- glycosylated forms of PrPSc after 72 hrs of spermine treatment. (f) CAD22L 
cells showing reduced immunofluorescence for PrPSc after 72 hrs of spermine treatment (N = 2). (g–i) Reduced 
expression of total PrPSc and PrPSc glycoforms in CAD22L cells, after 72 hrs of spermine treatment (N = 2). 
PrPSc glycoforms are shown with red arrows. (j) Reduced DCF fluorescence in CAD22L cells after 72 hrs of 
spermine treatment (N = 2). (k) Significantly reduced DCF mean intensity in CAD22L cells. Scale bar = 10 μm. 
Respective full length blots are shown in Supplementary Fig. 3. Abbreviations used: Chloroquine (CQ), 
Transmission Electron Microscopy (TEM), Dichlorofluorescein (DCF).
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Spermine clears prion aggregates by enhancing autolysosomal flux. Spermine is known to induce 
autophagy in the human fibrosarcoma cell line HT108021. We therefore investigated if spermine has a similar 
effect on the autophagic flux in SMB.s15 cells. Cells were treated both with the 5 μM spermine and 10 μM CQ 
for 24 hrs. A significant increase in the number of LC3 positive vesicles was observed after 24 hrs of spermine 
treatment (Fig. 3a,b). It is important to note that the morphology of LC3 punctae showed distinct changes when 
CQ was added into the media to stop the autophagic flux. The LC3 punctae were observed to be bigger in size 
and localised to circular vesicle-like structures upon CQ treatment compared to no treatment or treatment with 
spermine where numerous tiny LC3 punctae were observed. We also observed a significant increase in lysosomes 
using Lyso-ID a live dye for staining lysosomes (Fig. 3c,d). After 24 hrs spermine treatment we observed an 
increased conversion of LC3-I to LC3-II by WB with LC3 antibody compared to untreated cells with and without 
CQ treatment demonstrating an increased autophagic flux (Fig. 3e,f). In summary spermine treatment is not only 
able to enhance the number of autophagosomes but it is also making more lysosomes available for degradation.
We further investigated the levels of PrPSc aggregates within autophagosomes/autolysosomes after 0, 24 and 
72 hrs of spermine treatment and 16 hrs CQ in the SMB.s15 cells. The cells were stained with BC6 and LC3 and 
observed under confocal microscope. After 24 hrs of treatment (Fig. 3g second column) there were fewer PrPSc 
aggregates in the LC3 marked autolysosomes when compared to 0hrs i.e. untreated SMB.s15 cells (Fig. 3g first 
column) and by the end of 72 hrs there were minimal LC3 positive autolysosomes or PrPSc aggregates remain-
ing (Fig. 3g last column) indicating that spermine’s action has effectively cleared the aggregates within these 
cells. This result further confirms the reduced levels of PrPSc seen on spermine treatment in SMB.s15 and CAD 
cells (Fig. 2a,b,f). After 72 hrs of treatment many cells showed empty vesicles by TEM (Fig. 3h,i), compared to 
untreated SMB.s15 cells full of vesicles with aggregates (Fig. 1d, SMB.s15), these are single membrane vesicles 
likely to be autolysosomes which have digested the PrPSc aggregates and thus cleared of any protein aggregates 
(Fig. 3g,h).
Blocking formation of active autophagosomes with PI3K inhibitor LY294002 and silencing 
essential autophagy gene Atg5 prevents cells from clearing prion aggregates. LY294002 
(2-(4-morpholinyl)-8-phenylchromone) is a potent, cell permeable inhibitor of phosphatidylinositol 3-kinase 
(PI3K) and a known inhibitor of autophagosome formation29. Treatment of SMB.s15 cells with 40 μM of 
LY294002, with and without 10 μM of CQ reduced both LC3-I and its lipidated form LC3-II (Fig. 4a). When 
the cells were treated with 40 μM of LY294002 in the presence of 5 μM spermine for 24 and 72 hrs, no difference 
in PrPSc accumulation was detected compared to untreated samples (data not shown). However, when the cells 
treated with 5 μM spermine for 72 hrs were given 40 μM LY294002 and 10 μM CQ together for 16 hrs to assess the 
accumulation of PrPSc aggregates and stained with LC3 and BC6, increased accumulation of PrPSc aggregates was 
observed in the cytoplasm (Fig. 4b). Furthermore, upon LY294002 treatment we observed a significant reduc-
tion in the colocalisation of LC3 positive punctae to the PrPSc aggregates (Fig. 4c) compared to SMB.s15 cells 
treated with 10 μM CQ only (Fig. 1i, CQ treatment and Fig. 3g first column) where the PrPSc aggregates were seen 
surrounded by LC3 positive vesicles with a high degree of co-localization. A significant decline in correlation 
between LC3 punctae and PrPSc aggregates was observed upon LY294002 treatment (Fig. 4d). Moreover, TEM of 
the cells treated with 5 μM spermine for 72 hrs and given 40 μM LY294002 and 10 μM CQ for 16 hrs clearly show 
aggregates lying in the cytoplasm around empty vesicles (Fig. 4b). Again these images are clearly distinct from 
the CQ treated SMB.s15 cells, in which all the PrPSc aggregates were observed inside vesicles (Fig. 1d SMB.s15) or 
very few aggregates seen in the autolysosomes on spermine treatment (Fig. 3h). We further silenced the essential 
autophagy gene Atg5 using siRNA. Atg5 is required for the formation of active autophagosomes30. Silencing of 
Atg5 in SMB.s15 cells resulted in reduced Atg5 expression (Fig. 4f) and complete loss of LC3 punctae (Fig. 4e, the 
last two rows). Interestingly silencing of Atg5 resulted in a significant increase in PrPSc aggregates which could not 
be rescued by spermine treatment (Fig. 4e,g). These results clearly indicate that aggregate clearance by spermine 
is autophagy dependent and no engulfment of PrPSc aggregates takes place in the cytoplasm when autophagy is 
inhibited.
Spermine increases the acetylation of proteins involved in retrograde transport. Acetylation of 
proteins is known to control the process of autophagy31. We therefore used an affinity purification mass spectrom-
etry (MS) approach in order to examine the acetylation of proteins and thus determine spermine’s mechanism of 
action. Cytoplasmic lysates from SMB.s15 cells were pulled down with an acetylated lysine antibody after 0, 24 
and 72 hrs of treatment with spermine. These pull downs were trypsin digested and analysed by nanoLC-MS. We 
observed a significantly greater number of potentially acetylated proteins identified by MS after 24 hrs spermine 
treatment compared to 72 hrs, untreated, and beads alone control. Staining with InstantBlue protein stain showed 
a similar increase at 24 hrs on the gels compared to total protein blots (Supplementary Fig. 1b). The proteins with 
high mascot scores and increased number of peptide matches after 24 hrs treatment were cytoskeletal tubulins 
(Tubulin alpha1B/1C, Tubulin beta-5 chain, Tubulin beta-4B) (Supplementary Fig. 1c). These high scores and 
increased peptide matches were consistent for all three MS runs. This suggests these proteins are either increased 
in expression or acetylated by spermine treatment. To further verify the MS results two different antibodies were 
used against acetylated alpha tubulins (6-11B-1 and Lys40) and assessed both by WB and immunofluorescence. 
An up regulation in both total and acetylated alpha tubulins was observed following 24 hrs of spermine treatment 
(Fig. 5a lane 1, 2 & 3) on WBs when compared to β-actin expression (Fig. 5a lane 4, 5b). A similar result was also 
seen on the acetylated-lysine pull down product, supported by the observation that these proteins were reduced 
both in untreated and the beads alone control (BAC) (Fig. 5a lane 5) supporting our observation from the LC-MS 
data (Supplementary Fig. 1b). Further confocal imaging of SMB.s15 cells treated with 5 μM spermine for 24 and 
72 hrs was carried out after staining with both of the acetylated alpha tubulin antibodies. An increase in acetylated 
alpha tubulins was observed at 24 hrs (Fig. 5d) and additionally an increased colocalization of LC3 punctae on 
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Figure 3. Spermine clears prion aggregates by enhancing autolysosomal flux. SMB.s15 cells were either left 
untreated or treated with 10 μM CQ or treated with 5 μM Spermine alone or 5 μM Spermine and 10 μM of 
CQ for 24 hrs. (a) Representative images showing increased number of LC3 positive vesicles on spermine 
treatment (N = 3). (b) Significantly increased LC3 positive vesicles on spermine + CQ treatment compared 
to control + CQ treatment. (c) Representative images of increased number of Lyso-ID positive lysosomes on 
spermine treatment (N = 3). (d) Significantly increased lysosomes on spermine treatment. (e) Representative 
immunoblot to show increased conversion of LC3I to LC3II on spermine and CQ treatment (lanes 3, 4) 
compared to untreated cells (Lanes 1, 2) (N = 3). (f) Quantification of LC3II/ LC3I ratio as a marker of 
autophagic flux. SMB.s15 cells were treated with 5 μM spermine for 0, 24 and 72 hrs and 10 μM of CQ was 
given 16 hrs before the end point of spermine treatment to visualise the autolysosomes. (g) Representative 
immunofluorescence images of SMB.s15 cells stained for PrPSc and LC3 antibodies (N = 3). (h) Representative 
TEM image after 72  hrs of spermine treatment showing vesicles with reduced aggregates, area inside the 
circle is enlarged to show the vesicles (N = 2). (i) Vesicles with significantly reduced PrPSc aggregates on 
72 hrs of spermine treatment. Scale bar for confocal images = 10 μm. Respective full length blots are shown in 
Supplementary Fig. 3. Abbreviations used: Chloroquine (CQ), Transmission Electron Microscopy (TEM).
www.nature.com/scientificreports/
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Figure 4. Blocking formation of active autophagosomes with PI3K inhibitor LY294002 and Atg5 siRNA leads 
to failure of clearance of prion aggregates. SMB.s15 cells were treated with 40 μM PI3K inhibitor LY294002 for 
16 hrs to block the formation of autophagosomes. (a) Representative immunoblot to show reduced LC3-I and 
LC3-II after LY294002 treatment, lane 3 and 4. (b) Representative TEM image showing aggregates scattered in 
the cytoplasm with empty vesicles after treatment with 5 μM spermine for 72 hrs, LY294002 and 10 μM CQ for 
the last 16 hrs. (c). Representative immunofluorescence images showing reduced colocalisation of LC3 with 
PrPSc aggregates after treatment with 5 μM spermine for 72 hrs, LY294002 and 10 μM CQ for the last 16 hrs.  
(d) Significantly reduced colocalisation between LC3 and PrPSc aggregates on LY294002 treatment. For the Atg5 
siRNA treatment, the cells with either treated with 10 μM of CQ or 5 μM spermine and10μM of CQ for 24 hrs 
post transfection. (e) Representative immunofluorescence images showing reduced LC3 punctae and increased 
prion aggregates on treatment with Atg5 siRNA when compared to scrambled control siRNA. Treatment with 
spermine does not reduce the number of aggregates after Atg5 siRNA treatment (last lane). (f) Western blot 
to show reduced Atg5 expression on treatment with Atg5 siRNA when compared to scrambled control siRNA 
and the loading control β- actin. (g) Graph showing a significant increase in the number of PrP aggregates on 
spermine treatment post Atg5 siRNA treatment compared to spermine treated cells from scramble control 
siRNA. N = 2, Scale bar = 10 μm. Respective full length blots are shown in Supplementary Fig. 3. Abbreviations 
used: Chloroquine (CQ), Transmission Electron Microscopy (TEM).
www.nature.com/scientificreports/
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Figure 5. Spermine increases the acetylation of proteins involved in retrograde transport. SMB.s15 cells were 
treated with 5 μM Spermine for 0, 24 and 72 hrs; cytoplasmic extracts were used both for immunoprecipitation 
(IP) with anti-acetyl lysine antibody and run on WB or run directly on WB. (a) Immunoblotting with total 
alpha tubulin (lane1), two different acetyl-alpha tubulin antibodies (6–11B-1 and Lys40) show increased 
expression (lane 2 and 3) after 24 hrs spermine treatment, and loading control β-actin (lane 4) both from the 
cytoplasmic extract as well as from the immunoprecipitation product after IP with acetyl-lysine antibody 
(lane 5), BAC (lane 5 last row) (b) Graph showing relative expression levels of 6-11B-1 and Lys40 compared 
to β-actin. (c) WB shows increased expression of approx. 500 kDa Dynein-HC after 24 and 72 hrs of spermine 
treatment (d) Representative images with acetyl-alpha antibodies (6-11B-1, first lane) (Lys40, second lane) show 
increased expression on 24 hrs spermine treatment. (e) Representative images with increased colocalisation of 
bright LC3 punctae with acetyl-alpha antibody (6-11B-1) after 24 hrs spermine treatment. Scale bar = 10 μm,  
N = 3 for LC-MS, N = 2 for WB and immunofluorescence. Respective full length blots are shown in 
Supplementary Fig. 3. Abbreviations used: Immunoprecipitation (IP), Western blot (WB), Beads Alone Control 
(BAC), Liquid chromatography–mass spectrometry (LC-MS).
www.nature.com/scientificreports/
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acetylated alpha tubulins was apparent after 24 hrs of spermine treatment compared to untreated cells (Fig. 5e). 
Furthermore, MS results from anti-acetyl lysine pull downs also identified dynein-HC (Supplementary Fig. 1b) 
after 24 hrs of spermine treatment. However, we were unable to determine the acetylation status of the dynein-HC 
as there is no acetylated dynein antibody available. It may well not be acetylated itself, rather identified here as 
it has strong affinity for tubulins32. To identify the most likely explanation the expression of total dynein-HC 
in the cytoplasmic extract was assessed on spermine treatment and an increase in its expression both at 24 and 
72 hrs post spermine treatment was observed (Fig. 5c). These results strongly suggest an increased acetylation of 
cytoskeletal proteins involved in retrograde transport of autophagosomes on spermine treatment.
Microtubule protein Tubb6 binds to prion aggregates and targets them to autophagosomes. 
Using affinity-purification methods coupled with MS we investigated whether there are any specific proteins 
which bind to PrPSc aggregates and chaperone them to autophagosomes. Immunoprecipitation (IP) was carried 
out with prion specific antibody (BC6) in SMB.s15 cell lysates with and without CQ treatment. Simultaneous 
pull downs were carried out with lysates including beads without antibody to check for non-specific binding. 
On-bead protease digestion was carried out before MS runs. While a number of protein hits were obtained from 
each pull down only three proteins (Tubb6, Hsp47 and Ubap21) were selected as potential interactors based on 
their presence in the CQ treated samples, reduced levels as reflected by mascot scores and the number of peptides 
or the absence from untreated samples and absence from pull downs using beads alone control (without anti-
body) (Supplementary Fig. 2). In order to establish the localisation of these target proteins with respect to PrPSc 
aggregates, SMB.s15 cells were co-stained with antibodies against these proteins and BC6 after CQ treatment. 
Confocal images clearly showed the colocalisation of Tubb6 in circular vesicles with PrPSc aggregates (Fig. 6a row 
1) whereas the other two targets, HSP47 and Ubap21 did not show similar colocalisation (Fig. 6a row 2, 3). We 
also observed a trend towards increased expression of Tubb6 after CQ treatment in WB (Fig. 6b,c). We further 
validated Tubb6 for its binding efficiency with PK resistant PrP. The resultant BC6 pull down product and BAC 
was run on WBs and immunoblotted for Tubb6 (Fig. 6d, 1, 2), and PK digested bead product was immunoblotted 
for PrPSc (Fig. 6d, 3). Both Tubb6 and PrPSc were found in the IP products, demonstrating Tubb6 does bind to 
PrPSc. In order to confirm this binding, we reversed the IP and immunoprecipitated with Tubb6 and observed the 
expression of both the Tubb6 and PrPSc in the IP product (Fig. 6e 1 & 2).
We further asked whether Tubb6 has a more specific role in targeting PrPSc aggregates to the autophagosomes 
using RNAi on SMB.s15 cells (Fig. 6f). Our experiments show an increase in PrPSc aggregates after Tubb6 siRNA 
treatment compared to scramble siRNA control (Fig. 6g,h). These aggregates are not targeted to autophagosomes 
as shown in Fig. 6i lower panel where these protein aggregates can be seen around the bright punctate LC3 com-
pared to scramble siRNA treated control cells where protein aggregates can be seen localised with LC3 punctae 
(Fig. 6i upper panel). A significant negative correlation was observed between LC3 and BC6 on Tubb6 siRNA 
treatment when compared to the scrambled siRNA treated control (Fig. 6j).
Spermine enhances colocalisation of Tubb6 with PrPSc aggregates in aggresome like bodies. 
Aggresome formation is a process to bring potentially cytotoxic aggregates into one location for their eventual 
autophagic clearance from the cell33. After 24 hrs of spermine and CQ treatment we observed single aggresomes 
(Fig. 7a, spermine) which were bigger in size compared to PrPSc aggregates seen in SMB.s15 cells (Fig. 1i, CQ 
treated) and also fewer cells showed them without spermine treatment (Fig. 7a control, 7c). These aggresomes 
stained positive for both BC6 and Tubb6 (Fig. 7a) and BC6 and HDAC6 (an aggresome marker)34, confirming 
that they are indeed aggresomes (Fig. 7b). It is well established that aggresome formation is a cytoprotective 
response to sequester potentially toxic misfolded proteins and facilitate their clearance by autophagy35. Thus, our 
data demonstrates that spermine treatment is able to facilitate formation of these aggresomes in which Tubb6 is 
seen colocalising to PrPSc aggregates.
Discussion
In this study we have demonstrated that the natural polyamine spermine can clear the prion aggregates in prion 
infected cell cultures. We also show that spermine treatment can significantly reduce the associated ROS in neu-
ronal cells infected with the prion agent 22L. This aggregate clearance is dependent on the cellular autophagy 
process. Our affinity-MS experiments provide strong evidence of an increase in acetylated tubulins known to have 
role in stabilising microtubules and facilitating cellular retrograde transport of autophagosomes. Using a similar 
approach, we have also identified microtubule protein Tubb6 as a binding partner of PrPSc aggregates which tar-
gets them to autophagosomes.
Various polyamine based strategies have been tested for degradation of detergent-insoluble and PK-resistant 
PrPSc. Exogenous administration of polycationic DOSPA bound to liposomes was found to significantly reduce 
the levels of PrPSc in ScN2a cells36. PPI Poly(propylene imine) dendimers, a group of branched polyamines have 
been implicated in denaturation of PrPSc and its clearance, this is shown to be occurring inside lysosomes37,38. 
However, in the absence of autophagy markers the role of the autophagy pathway during the clearance of PrPSc in 
these studies could not be assessed. Furthermore, polyamine spermidine has been shown to successfully amelio-
rate neurodegeneration in various in vitro, mouse and fly model of diseases including ischaemia39, normal tension 
glaucoma40, proteinopathies of the TAR DNA-binding protein 4341 Parkinson’s disease42 and in a yeast model of 
prion diseases43. However, its derivative spermine has not yet been investigated for its therapeutic effects.
A study by Bera and Nandi in 2007 reported spermine as a more potent polyamine than spermidine in inhib-
iting nucleic-acid-induced polymerisation of prion protein20 and its role as a free radical scavenger has also been 
shown22. Spermine is a mimetic of caloric restriction (CR) and the role of caloric restriction in enhancing longev-
ity is well known. However its role in degradation of protein aggregates has not been addressed in mammalian 
systems44. CR mimetics like spermidine are known to enhance longevity via enhancing autophagy45, this could be 
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Figure 6. Microtubule protein Tubb6 binds to prion aggregates and targets them to autophagosomes. All 
the experiments were performed on SMB.s15 cells with or without 10 μM CQ for 16 hrs. (a) Representative 
immunofluorescence images of Tubb6, lane 1 (N = 3), HSP47, lane 2 (N = 2) and Ubap21, lane 3 (N = 2) 
with PrPSc showing localisation of individual protein targets with respect to PrPSc in the cytoplasm. (b) 
Representative WB show increased expression of Tubb6 on CQ treatment (N = 2). (c) Relative expression 
levels of Tubb6 compared to β-actin on CQ treatment. (d) (1) IP with BC6 (anti-PrP antibody) immunoblotted 
with Tubb6, red arrow indicates approx. 53 kDa Tubb6 band (2) Beads alone control (3) immunoblotted for 
BC6 after PK treatment. (e) Reverse IP with Tubb6 (1) immunoblotted with Tubb6 (2) immunoblotted for 
BC6 after PK treatment. (f) Representative WB to show reduced expression of Tubb6 on siRNA treatment. 
(g) Representative immunofluorescence images of increased number of PrPSc aggregates after Tubb6 siRNA 
treatment compared to scramble siRNA, magnified area inside the white square to show PrPSc aggregates are 
surrounded by Tubb6 in scramble siRNA control (N = 3). (h) Increased numbers of PrPSc aggregates on Tubb6 
siRNA treatment (non-significant P = 0.0668). (i) Representative immunofluorescence staining for LC3 and 
BC6 after 10 μM CQ treatment showing no targeting of PrPSc aggregates to LC3 positive punctae after Tubb6 
siRNA treatment compared to the control cells treated with scramble siRNA (N = 3). (j) A significant negative 
www.nature.com/scientificreports/
1 1SCiENtifiC REPORTS |  (2018) 8:10004  | DOI:10.1038/s41598-018-28296-y
supported with the observation that high levels of spermine were measured in the whole blood of healthy nona/
centenarians46. Thus, both spermine and spermidine may have a role in clearance of protein aggregates seen dur-
ing neurodegeneration associated with aging.
We and others have reported impaired autophagy pathway in aging cells47,48 and it has been shown that the 
aging brain can trigger the formation of amyloid aggregates though the mechanisms remain unknown49. Massive 
accumulation of autophagic vacuoles within large swellings along dystrophic and degenerating neurites is com-
mon in AD and other protein misfolding diseases and this could be related to defects in various steps of the auto-
phagy pathway such as initiation of autophagosome formation50,51, cargo recognition52, autophagosome-lysosome 
fusion53,54, lysosomal proteolysis55,56 as well as a defect in retrograde transport responsible for the trafficking 
of cargo filled autophagosomes from the cellular periphery to the lysosomes residing near the nuclear core57. 
While compounds enhancing autophagy are being tested in various in vitro and in vivo models of neurodegen-
eration8,14,41,43,58 their clinical success is still to be proven. Our experiments with the natural polyamine spermine 
reveal not only an increase in the number of active autophagosomes but also in number of lysosomes. This two 
way enhancement (Fig. 3a,c) provides the cells with an opportunity to sequestrate more of the misfolded protein 
aggregates and also provide access to increased number of lysosomes with proteases for their degradation. As the 
PrPSc is likely to be trafficked via endosomes59 from the cellular surface and passed over to autophagosomes to 
be delivered to lysosomes, an efficient retrograde transport system consisting of stable microtubules is a key to 
successful delivery of cargo filled autophagosomes to nuclear periphery where the bulk of lysosomes assemble.
Microtubular proteins often function in complexes and are heavily regulated at the post-translational levels. 
Acetylation levels of many of these proteins may provide a pro-autophagic response and this has been shown for 
compounds like spermidine and resveratrol60. Acetylated microtubules are required for the fusion of autopha-
gosomes with lysosomes to form autolysosomes61 and to facilitate phagophore/autophagosome formation by 
specifically recruiting BECN1, class III PtdIns3K, WIPI1, ATG12–ATG5 and LC3-II on unstable microtubules62,63 
and also to facilitate the movement of mature autophagosomes (marked with LC3-II) along stable microtubules64. 
Lys40 acetylation marks stable microtubules and it has been shown that α-tubulin acetylation at Lys40 increases 
the recruitment and mobility of KIF1 and dynein both in vitro and in vivo65. Dynein-mediated autophagosome 
trafficking has also been demonstrated to contribute to the formation of autolysosomes and thus enhance the 
autophagic flux66. The role of dynein and tubulins become more critical in neuronal cells as they are employed for 
the retrograde transport of aggregated proteins from the neurites and synaptic terminals to mature acidic lyso-
somes which are relatively enriched in the soma. Deficiency of these could result in accumulation of autophagic 
vesicles in these regions. It has been reported that spermidine promotes acetylation of histones and thus regulate 
the expression of autophagy genes (17); however the effect of these polyamines on cytoskeletal proteins has yet to 
be investigated. We speculate that spermine may act in a similar fashion. We hypothesise that spermine treatment 
is able to facilitate retrograde transport by hyperacetylating tubulins and increasing the expression of Dynein-HC.
Along with efficient transportation, selective targeting of the cargo for autophagic degradation is known to 
increase the efficiency of aggregate degradation67. The presence of γ-tubulin in aggresomes is reported in few 
studies68,69. Using the affinity purification-MS approach we have shown for the first time that Tubb6 can be seen 
co-localised to prion aggresomes. Additionally, silencing of Tubb6 results in an increased number of prion aggre-
gates and mis-targeting of prion aggregates to the LC3 positive autophagosomes, thus establishing its quintessen-
tial role in tagging PrPSc aggregates for degradation via autophagy. Our online search at iLIR database70 shows the 
presence of at least 4 LIR (WxxL) motifs in the Tubb6 sequence with a PSSM score of 5, 7, 7 and 8 respectively, 
indicating the presence of motifs necessary for interaction with Atg8 (LC3)-family of proteins indicating a pos-
sibility of Tubb6 being an autophagy adaptor for prion aggregates, however more experiments will be needed to 
establish its bona fide role as an autophagy adaptor. Moreover, aggresome formation is a major cytoprotective 
mechanism formulated by a cell overwhelmed with protein aggregates, whereby cellular machinery attempts 
to centralize the collection of cargo filled autophagosomes to enhance the chances of their fusion with lyso-
somes and later degradation33,71. This seems to be aided by spermine along with acetylating microtubules which 
is known to facilitate transportation of autophagic vesicles. We also hypothesise that Tubb6 is a novel member of 
the aggresome-autophagy pathway which also includes HDAC6, dynein, acetylated tubulins and LC3.
Our results clearly show that autophagy induction clears prion aggregates. Interestingly, recent work has 
demonstrated that mTOR inhibitor rapamycin strongly inhibits exosomal prion release which could have effects 
on lateral transfer of prions72. This action could be because of the enhanced flow of prion aggregates through 
autophagy pathway and their subsequent degradation which when blocked could lead to exosomal prion release. 
Although the present study does not provide any evidence of prion clearance by spermine treatment in vivo, our 
results in the in vitro systems clearly suggest spermine and the pathways modulated by it as a new therapeutic 
target of future research for protein misfolding diseases (Summary of the results, Fig. 8).
Methodology
Cell lines. SMB cells. This SMB.s15 cell line was established originally by culture from a brain taken from 
a mouse clinically affected by the Chandler scrapie isolate and is shown to be a cell line of mesodermal origin23. 
They were cultured 0.5–1.0 × 105 cells/ml in complete DMEM (Invitrogen) medium supplemented with 10% FBS 
in 12 well plates and 1 in 10 dilution for growing in T75 culture flasks. These cell lines have PrPSc aggregates. The 
correlation between LC3 and PrPSc aggregates after Tubb6 siRNA treatment compared to the control cells 
treated with scramble siRNA. Scale bar = 10 μm. Respective full length blots are shown in Supplementary Fig. 3. 
Abbreviations used Chloroquine (CQ), Proteinase K (PK), Immunoprecipitation (IP).
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pentosan sulphate (PS) cured form of SMB.s15 cell line is called SMB-PS and is used as a control cell line as it 
lacks disease associated PrPSc aggregates.
CAD cells. These are mouse cells infected/uninfected with the prion strain 22L73. They were cultivated in 
Opti-MEM (Invitrogen) supplemented with 10% fetal calf serum (FCS). The cells were differentiated into neu-
rons by cultivation in Dulbecco’s modified Eagle’s medium (DMEM)/F12 medium (BioWhittaker) supplemented 
with 0.5% FCS for 6 days26.
Antibodies. Following antibodies were used, mouse monoclonal ROS-BC6 (BC6) (anti-prion) 1.3 mg/ml (TSE 
Resource Centre, Cat no: RC 06374), rabbit polyclonal anti-LC3 (MBL, PM036) 1:3000 for WB and 1:300 for imag-
ing, anti-acetyl alpha tubulin (6-11B-1) (Santa Cruz biotech, sc-23950) and mouse monoclonal anti- acetylated 
Figure 7. Spermine enhances colocalisation of Tubb6 with PrPSc aggregates in aggresomes. SMB.s15 cells 
were treated with10 μM CQ or treated with 5 μM of spermine and 10 μM CQ for 24 hrs. (a) Representative 
immunofluorescence images of spermine + CQ treated cells showing cells with aggresomes stained with 
antibodies for Tubb6 and PrPSc aggregates (lower lane) compared to untreated control cells + CQ (upper 
lane) (N = 3). (b) Representative immunofluorescence image showing colocalisation of HDAC6 and PrPSc 
aggregates (N = 3). (c) Significantly increased number of cells per microscopic area showing aggresomes on 
spermine + CQ treatment when compared to untreated control cells+ CQ, each microscopic area contained 
5–15 cells, total of 10 microscopic areas were counted. Scale bar = 10 μm. Abbreviations used Chloroquine 
(CQ).
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tubulin (Lys40) (Proteintech, cat no 66200-1-Ig) both used at 1:1000 for WB and 1:300 for imaging, mouse mono-
clonal anti-DyneinHC (C-5) (Santa Cruz biotech, sc-514579) 1:1000 for WB, rabbit polyclonal anti-Tubb6 (Aviva 
systems biology, ARP60382_P050) 1:1000 for WB and 1:300 for imaging, rabbit polyclonal anti-HSP47 (Abcam, 
ab77609), rabbit polyclonal anti-UbAP2L (Thermo scientific, PA5-29520) both 1:300 for imaging, rabbit mono-
clonal anti-HDAC6 (Abcam ab133493) used at 1:100 for imaging and rabbit polyclonal anti-beta actin (GeneTex, 
cat no GTX109639), Rabbit Polyclonal ATG5 (Sigma, A0731), used at 1:1000 for WB, secondary antibodies goat 
anti rabbit 488 (Thermo Fisher Scientific A11034) and goat anti mouse 647 (Thermo Fisher Scientific A21236) 
were both used at 1:500 for microscopy.
Spermine. Spermine (product code 18041) was bought from Cayman chemicals. 1M stock was prepared in 
distilled water and stored at −80 °C for long term usage. Final dilutions for experiments were made in the full 
DMEM media before adding into cultures.
Cellular lysates and protease digestion. The cells were washed twice with cold phosphate buffered saline (PBS), 
and whole-cell lysates were prepared at 4 °C in TL1 lysis buffer (50 mM Tris-HCl [pH 7.4], 0.5% Triton X-100, 
0.5% sodium deoxycholate). Lysates were clarified by centrifugation at 1000 × g for 2 min, and the total protein 
concentration was estimated by microBCA assay (Pierce). To analyse the PrPC content, 50 µg of protein was meth-
anol precipitated, centrifuged at 22,000 × g for 20 min and pellets were dried. For PrPSc, one hundred micrograms 
of protein in 200 µl TL1 buffer was digested at 37 °C for 2 hrs with 4 µg proteinase-K (PK) per 1 mg of protein as 
published previously75. PK digestion was stopped by addition of four volumes of absolute methanol. After over-
night incubation at −20 °C, samples were further centrifuged at 22,000 × g for 30 min, and pellets were dissolved 
in 20 μl 2X Laemmli sample buffer and denatured by boiling at 100 °C for 5 min for SDS-PAGE analysis.
TEM. Cells post spermine or CQ treatment were lifted using Trypsin/EDTA, spun down and washed twice 
with PBS and fixed for 3 hrs at RT in 2.5% glutaradehyde in 4% PFA. Washed twice in PBS, finally suspended in 
PBS and handed over for sectioning. Samples were then post-fixed in 1% Osmium Tetroxide in 0.1 M Sodium 
Cacodylate for 45 min, and then washed in three 10 min changes of 0.1 M Sodium Cacodylate buffer. These sam-
ples were then dehydrated in 50%, 70%, 90% and 100% ethanol (X3) for 15 min each, then in two 10 min changes 
in Propylene Oxide. Samples were then embedded in TAAB 812 resin. Sections, 1 μm thick were cut on a Leica 
Ultracut ultramicrotome, stained with Toluidine Blue, and viewed in a light microscope to select suitable areas 
Figure 8. A pictorial summary of how spermine treatment facilitates degradation of prion aggregates in SMB.
s15 cells. Spermine treatment clears prion aggregates by enhancing the autolysosomal flux both by enhancing 
the number of mature autophagosomes and lysosomes. Treatment with spermine enhances the expression of 
acetylated tubulins and increases the expression of dynein-HC. Both acetylated tubulins and dynein-HC are 
known to have a role in stabilising microtubules for retrograde transport of autophagosomes from the cellular 
periphery to the perinuclear location where the lysosomes reside. Furthermore, spermine treatment facilitates 
formation of prion aggresomes bound to Tubb6 for their delivery to autophagosomes for their clearance (b). 
Compared to the untreated control cells (a).
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for investigation. Ultrathin sections, 60 nm thick were cut from selected areas, stained in Uranyl Acetate and Lead 
Citrate then viewed in a JEOL JEM-1400 Plus TEM. Representative images were collected on a GATAN OneView 
camera.
Confocal Microscopy. Zeiss LSM 710 inverted confocal microscope was used to obtain all the confocal micros-
copy images. SMB and CAD cells were grown on cover slips in 24 well plates (at a concentration of 4 × 106). In 
general cells were fixed for 20 min in ice cold 4% PFA at 4 °C. Fixed cells were washed and permeabilised with 
0.1% triton X100 for 10 min at 4 °C and blocked with 2% FCS for 30 min at RT before staining with primary anti-
bodies. To observe PrPSc aggregates an additional step of treating the cells with 5M guanidine isothiocynate for 
5–10 min at room temperature after permeabilising them with 0.5% tritonX-100 in PBS was employed. Live imag-
ing for lysosomes was done using LYSO-ID red dye (Enzo life sciences, ENZ-51005-0100) (1:1000) by incubating 
the cells for 30 min at 37 °C. Proteostat dye (Enzo life sciences, ENZ-51035) was used to visualise the aggregates, 
cells were washed and fixed and permeabilised as above and incubated with proteostat dye and Hoechst (1:100) 
and incubated in dark for 30 min at RT, and cells were later washed and mounted on glass slides.
MTT, TMRE and ROS Assay. Cell viability was measured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) cell viability kit (Biotium, 3006) as described by manufacturers. In short 1 × 105 cells 
were seeded in 96 well plate, cells were treated with different doses of spermine for 72 hrs. 10 μl of MTT solution 
was added to 100 μl medium in each well and incubated for 2 hrs at 37 °C. After 2  hrs, 200 μl of DMSO was added 
directly into the media. Absorbance was measured at 570 nm.
Mitochondrial membrane potential was measured using TMRE assay kit from (Abcam, ab113852) using man-
ufactures instructions. In short 1 × 105 cells were seeded in 96 well plate and treated with 5 μM of spermine for 
72 hrs. Cells were then stained with 500 nM of TMRE for 20 min at 37 °C, washed twice with PBS and analysed at 
549/575 Ex/Em using spectrophotometer (BioTeK Synergy HT).
Intracellular ROS was detected using Dihydrofluorescein diacetate (DCFH-DA) (Sigma, 292648), CAD cells 
were washed of the media and PBS was added and 5 μM of DCFH-DA was added to the cultures and cells were 
incubated at RT in dark for 30 min. The cells were washed 3X with PBS, mounted with prolong gold antifade 
reagent (Thermo fisher scientific, P36930) and visualised immediately using Zeiss LSM 710 inverted confocal 
microscope.
Immunoblotting. Protein was extracted using radioimmunoprecipitation assay buffer with supplemental Halt 
Protease Inhibitor Cocktail EDTA-free (Thermo scientific, 87785). Protein content was measured using Pierce™ 
BCA Protein Assay Kit (Thermo scientific, 23225) and samples boiled with 4X sample buffer and then run on a 
4–12% Bis-Tris gel (Invitrogen) for PrP, LC3, tubb6 and acetylated tubulins. To resolve 500 kDa DyneinHC on gel, 
3–8% Tris-acetate gels were used (Invitrogen). Proteins were transferred to PVDF membranes (Immobilon-FL 
transfer membrane, IPFL00010) and blocked overnight in LICOR blocking buffer. The membranes were incu-
bated in primary antibodies (1: 3000) in LICOR blocking buffer, at 4 °C overnight. For all the blots β-actin or 
β-tubulin were run on the same gel except for the DyneinHC where β-actin was run separately. Secondary anti-
bodies used were goat α-rabbit IRDye 680RD (926-68071) or goat α-mouse IRDye 680 RD (926-68070) (Licor, 
Cambridge, UK). Blot detection was carried out using Odyssey CLx Infrared Imaging System. The default setting 
used for blot image acquisition on Odyssey CLx Infrared Imaging system was resolution 169 μm, quality medium, 
laser intensities between 5–1.5.
Acetyl-Lysine Enrichment. SMB.s15 cells were treated with 5 μM of spermine for 0, 24 and 72 hrs. Cells were 
washed and cytoplasmic extracts were made using Nuclear/Cytosol fractionation Kit from BioVision (K266). 
Fifty microliters of Pierce protein A/G Magnetic beads (Thermo scientific, 88802) were added to the protein sam-
ple equivalent to 200 μg of protein followed by incubation on a rotator for 1 h at RT to remove any non-specific 
binding of protein to the beads. The sample was then magnetically separated and the supernatant transferred to a 
new tube. Ten microliters of rabbit monoclonal anti-acetyl-lysine antibody (Proteintech, 66200-1-Ig) was added 
and the mixture incubated on a rotator at 4 °C overnight. The next day, 100 μl of beads were added to the sample 
followed by incubation on a rotator for 1 hr at 4 °C. The beads were washed five times with 1 ml of IP lysis buffer 
and separated into two equal portions, one half was given a final wash with LC-MS grade water before on bead 
digestion and MS identification and analysis and the other half was eluted from the beads by adding 2X Laemmli 
sample buffer and boiling at 95 °C for 15 min. These samples were spun at 1500 rpm for 2 min and the supernatant 
harvested and run for WB. A control with beads alone and no antibody was used in all the runs.
BC6 pull down. To identify specific binders for PrPSc, SMB.s15 cells were either treated with 10 μM CQ for 16 hrs 
or left untreated. 10 μM CQ was added to increase the likelihood of PrPSc being sequestered in autophagosomes/ 
autolysosomes hence increasing the likelihood of enriching the proteins binding to PrPSc being brought to auto-
phagosomes or autolysosomes. The protein extracts were made with IP lysis buffer, the rest of the procedure was 
same as described for acetyl lysine pull down except that anti PrP antibody BC6 was used for the pull down.
RNAi treatment. SMB.s15 cell 70% confluent was used for all the experiments. Standard siRNA treatment was 
followed, in short 6 μl of both the Tubb6 and control SiRNA mouse (Santa Cruz biotech, sc-141449, sc-37007) 
were used for transfection. The cells were left to incubate for 7 hrs at 37 °C, after which the transfection media was 
removed and cells were left in full media for 48 hrs before making extracts for WB or fixing them for microscopy 
or spermine treatment. For Atg5 siRNA studies 8 μl of both the Atg5 and control SiRNA mouse (Santa Cruz bio-
tech, sc-41446, sc-37007) were used for transfection.
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‘On-bead’ tryptic digestion and LC MS identification of proteins. Washed beads were resuspended in 10% 
Triflouroethanol (pH 8.0) with gentle vortexing for one hour and digested with sequencing grade modified 
trypsin (Promega), following reduction with 5 mM dithiothreitol and alkylation with 10 mM iodoacetamide. 
The resulting peptide mixture containing beads were spun at 800 × g and supernatant was collected. The digested 
peptides were cleaned up using Stagetips following a standard protocol76.
NanoflowLC-MS/MS was performed on a micrOTOF-II mass spectrometer (Bruker, Germany) coupled to 
an RSLCnano LC system (Thermo). Tryptic digest was delivered to a trap column (Acclaim PepMap100, 5 μm, 
100 Å, 100 μm i.d. × 2 cm) at a flow rate of 20 μL/min in 100% solvent A (0.1% formic acid in LCMS grade water). 
After 4 min of loading and washing, peptides were transferred to an analytical column (Acclaim PepMap100, 
3 μm, 100 Å, 75 μm i.d. × 25 cm) and separated at a flow rate of 300 nL/min using a 60 min gradient from 7% to 
35% solvent B (solvent B, 0.1% formic acid in acetonitrile). The eluted peptides from LC were electrosprayed 
directly on to the mass spectrometer for MS and MS/MS analysis in a data-dependent mode of acquisition. The 
m/z values of tryptic peptides were measured using a MS scan (300–2000 m/z), followed by MS/MS scans of the 
six most intense ions. Rolling collision energy for fragmentation was selected based on the precursor ion mass 
and a dynamic exclusion was applied for 30 sec.
Raw spectral data were processed with DataAnalysis (Bruker) software and the resulting peak lists were 
searched using Mascot 2.4 server (Matrix Science, London, UK) against Uniprot Mouse sequence database con-
taining 53,216 entries. Mass tolerance on peptide precursor ions was fixed at 25 ppm and on fragment ions at 
0.05 Da. The peptide charge was set to 2+ and 3+. Carbamidomethylation of cysteine was selected as a fixed 
modification and oxidation of methionine and de-amidation were chosen as variable modifications. False discov-
ery rate was limited to <1% for peptide IDs after searching decoy databases.
Statistical analyses were performed using Prism 7 for windows (GraphPad Software, Inc.). Error bars represent 
SEM, and p-values were calculated with a two-tailed Mann–Whitney test unless stated otherwise. The key for 
the p-values is *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ImageJ software was used to calculate the 
Spearman’s correlation (ρ) between BC6 (PrPSc aggregates) and LC3 punctae (active autophagosomes) to quantify 
the level of colocalisation. For immunofluorescence a minimum of 25 to maximum of 100 cells were analysed/ 
experiment.
Data Availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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